In AD patients, degeneration of SCN neurons, disruption of melatonin rhythms, and synergistic effects of β-amyloid (Aβ)/Tau pathology and neuroinflammation result in a fragmented sleep–wake cycle, diminished amplitude, and phase misalignment, which have profound adverse effects on cognitive function. The gene discussed is MAPT; the disease is Alzheimer disease.